Idiopathic
Pulmonary Fibrosis
(IPF)
Dr Helen Parfrey
Papworth Hospital, Cambridge
IPF
 What is IPF ?
 What causes pulmonary fibrosis ?
 How do I know if I have IPF ?
 How is it treated ?
Lung Structure
 The airways branch
within the lung
 End in air sacs or alveoli
 Sites where exchange
oxygen breathe in with
carbon dioxide breathe
out
What is pulmonary fibrosis?
 Scar tissue or collagen
builds up around the alveoli
- this process is termed
FIBROSIS
 Impairs gas exchange in the
lung
 Accumulation of scar tissue
over time permanently
destroys lung structure
 Leads to “honeycomb lung”
Fibrotic “Honeycomb” Lung
Normal Lung Fibrotic or Honeycomb Lung
IPF commonest form of
pulmonary fibrosis
IPFAutoimmune
disease
NSIP
SarcoidDrugs
Hypersensitivity
pneumonitisOccupation
related
Cause of IPF is unknown
Alveoli lining cells
Inhaled damaging
particles
Repair
processes
Normal
lung tissue
Scar tissue
Lung Fibrosis
Who gets IPF ?
 Males > Females (2:1)
 Increasing age (>60 yrs)
 Estimated 15000 people with IPF in UK
 5000 new cases IPF per year in UK
 Incidence increasing in worldwide
 Growing health concern
Risk factors for developing IPF
 Smoking (2.8 fold increased risk)
 Occupational exposures
 Hard woods, metals, asbestos
 Family history of pulmonary fibrosis
 Possibly gastro-oesophageal reflux disease
(GORD)
What are the symptoms of IPF?
Symptoms
 Cough
 Dry tickle
 Productive of sputum
 Short of breath with
activities
Limitations
 Symptoms common to
many lung diseases
 Delay in diagnosis
Establishing Diagnosis
 Clinical assessment
 Evaluate symptoms
 Occupational exposures
 Medications
 Family history
 Examination
 Oxygen saturation
 Clubbing of finger nails
 Listen to chest for “crackles”
Investigations
 Blood tests
 Lung Function Tests
 ForcedVital Capacity (FVC)
 DLco orTLco (gas transfer)
 Walk test
 6 minute walk test
 Shuttle walk test
Chest X-ray
Normal IPF
Lung Heart
Lungs are reduced in size and have
increased reticular markings
Chest CT Scan
Normal IPF
Lung
If diagnosis is uncertain…..
 Some circumstances the CT scan has unusual
features which are not typical for IPF
 May need a bronchoscopy
 May need a surgical lung biopsy
Usual Interstitial Pneumonia (UIP)
Normal Lung UIP
Establish Diagnosis
Clinical
• Symptoms
• Smoking history
• Exposures
• Features of CTD
• Examination
Investigations
• CXR
• CTThorax
• Blood tests
• Lung Function
Pathology
• Bronchoalveolar
lavage
• Surgical lung
biopsy
Multi-DisciplinaryTeam (MDT)
Discussion
IPF Progressive Disease
Bjoraker et al AJRCCM 1998; 157: 199-203
Median survival is 3 years from diagnosis
How to treat IPF
 No curative treatment other than lung transplant
 Aim of treatment is to slow rate of progression of
IPF
 Rate of progression is very variable
 Monitor change in lung function (FVC)
 Not all patients with IPF may treatment
What treatment options ?
Supportive
• Breathlessness management
• Oxygen
Symptoms
• Cough
Disease specific
• Medication
• Lung transplant
SupportiveTreatments
 Smoking cessation
 Breathlessness management
 Pacing, hand held fan
 Specialist clinic
 Medicines
 Pulmonary Rehab and exercise
 Improves strength and walk distance
 Palliative Care Services
Oxygen therapy
 Not for everyone with IPF
 People who are limited by low blood oxygen
 walking outside / gardening
 around the house
 at night
 all or most of the time
 Different types of oxygen
 Long term oxygen therapy (LTOT)
 Oxygen for exercise (ambulatory)
 Short burst
Treating Cough
 Cough suppression techniques –physiotherapy
 Clearing phlegm
 Mucolytic agents such as mucodyne, N-acetylcysteine
(NAC)
 Treat gastro-oesophageal reflux disease
 Cough suppressant medications
Preventing chest infections
 Vaccination
 Annual flu vaccine
 Pneumonia vaccine
 Prompt treatment of infections with antibiotics
Treatments for IPF
 Prednisolone and azathioprine +/- N-acetylcysteine
 Use of this has been questioned by interim report from the PANTHER
study in the USA
 May wish to discuss this treatment with your doctor
 Pirfenidone (Esbriet)
 First licensed treatment for IPF in Europe
 Recommended for mild to moderate IPF
 Named patient programme in UK
 Slow disease progression
 Side effects – skin rash, GI symptoms, liver impairment
 Discuss taking part in a clinical trial
 Discuss lung transplantation
Conclusions
 Number of challenges remain
 Establishing the diagnosis can be difficult
 Limited treatment options and accessibility
 Poorly identified patient needs
 Limited resources available for patients and families
 Promoting awareness and education
Questions

IPF Webinar for the British Lung Foundation 2012: Dr Helen Parfrey

  • 1.
    Idiopathic Pulmonary Fibrosis (IPF) Dr HelenParfrey Papworth Hospital, Cambridge
  • 2.
    IPF  What isIPF ?  What causes pulmonary fibrosis ?  How do I know if I have IPF ?  How is it treated ?
  • 3.
    Lung Structure  Theairways branch within the lung  End in air sacs or alveoli  Sites where exchange oxygen breathe in with carbon dioxide breathe out
  • 4.
    What is pulmonaryfibrosis?  Scar tissue or collagen builds up around the alveoli - this process is termed FIBROSIS  Impairs gas exchange in the lung  Accumulation of scar tissue over time permanently destroys lung structure  Leads to “honeycomb lung”
  • 5.
    Fibrotic “Honeycomb” Lung NormalLung Fibrotic or Honeycomb Lung
  • 6.
    IPF commonest formof pulmonary fibrosis IPFAutoimmune disease NSIP SarcoidDrugs Hypersensitivity pneumonitisOccupation related
  • 7.
    Cause of IPFis unknown Alveoli lining cells Inhaled damaging particles Repair processes Normal lung tissue Scar tissue Lung Fibrosis
  • 8.
    Who gets IPF?  Males > Females (2:1)  Increasing age (>60 yrs)  Estimated 15000 people with IPF in UK  5000 new cases IPF per year in UK  Incidence increasing in worldwide  Growing health concern
  • 9.
    Risk factors fordeveloping IPF  Smoking (2.8 fold increased risk)  Occupational exposures  Hard woods, metals, asbestos  Family history of pulmonary fibrosis  Possibly gastro-oesophageal reflux disease (GORD)
  • 10.
    What are thesymptoms of IPF? Symptoms  Cough  Dry tickle  Productive of sputum  Short of breath with activities Limitations  Symptoms common to many lung diseases  Delay in diagnosis
  • 11.
    Establishing Diagnosis  Clinicalassessment  Evaluate symptoms  Occupational exposures  Medications  Family history  Examination  Oxygen saturation  Clubbing of finger nails  Listen to chest for “crackles”
  • 12.
    Investigations  Blood tests Lung Function Tests  ForcedVital Capacity (FVC)  DLco orTLco (gas transfer)  Walk test  6 minute walk test  Shuttle walk test
  • 13.
    Chest X-ray Normal IPF LungHeart Lungs are reduced in size and have increased reticular markings
  • 14.
  • 15.
    If diagnosis isuncertain…..  Some circumstances the CT scan has unusual features which are not typical for IPF  May need a bronchoscopy  May need a surgical lung biopsy
  • 16.
    Usual Interstitial Pneumonia(UIP) Normal Lung UIP
  • 17.
    Establish Diagnosis Clinical • Symptoms •Smoking history • Exposures • Features of CTD • Examination Investigations • CXR • CTThorax • Blood tests • Lung Function Pathology • Bronchoalveolar lavage • Surgical lung biopsy Multi-DisciplinaryTeam (MDT) Discussion
  • 18.
    IPF Progressive Disease Bjorakeret al AJRCCM 1998; 157: 199-203 Median survival is 3 years from diagnosis
  • 19.
    How to treatIPF  No curative treatment other than lung transplant  Aim of treatment is to slow rate of progression of IPF  Rate of progression is very variable  Monitor change in lung function (FVC)  Not all patients with IPF may treatment
  • 20.
    What treatment options? Supportive • Breathlessness management • Oxygen Symptoms • Cough Disease specific • Medication • Lung transplant
  • 21.
    SupportiveTreatments  Smoking cessation Breathlessness management  Pacing, hand held fan  Specialist clinic  Medicines  Pulmonary Rehab and exercise  Improves strength and walk distance  Palliative Care Services
  • 22.
    Oxygen therapy  Notfor everyone with IPF  People who are limited by low blood oxygen  walking outside / gardening  around the house  at night  all or most of the time  Different types of oxygen  Long term oxygen therapy (LTOT)  Oxygen for exercise (ambulatory)  Short burst
  • 23.
    Treating Cough  Coughsuppression techniques –physiotherapy  Clearing phlegm  Mucolytic agents such as mucodyne, N-acetylcysteine (NAC)  Treat gastro-oesophageal reflux disease  Cough suppressant medications
  • 24.
    Preventing chest infections Vaccination  Annual flu vaccine  Pneumonia vaccine  Prompt treatment of infections with antibiotics
  • 26.
    Treatments for IPF Prednisolone and azathioprine +/- N-acetylcysteine  Use of this has been questioned by interim report from the PANTHER study in the USA  May wish to discuss this treatment with your doctor  Pirfenidone (Esbriet)  First licensed treatment for IPF in Europe  Recommended for mild to moderate IPF  Named patient programme in UK  Slow disease progression  Side effects – skin rash, GI symptoms, liver impairment  Discuss taking part in a clinical trial  Discuss lung transplantation
  • 27.
    Conclusions  Number ofchallenges remain  Establishing the diagnosis can be difficult  Limited treatment options and accessibility  Poorly identified patient needs  Limited resources available for patients and families  Promoting awareness and education
  • 28.